Titles
- Aligning maternal health policies with birthing people’s preferences and experiences1
- Alternative payment models and the slowdown in federal health care spending: testimony before the Committee on the Budget, United States Senate1
- American perspectives on racism and racial justice1
- An estimated 91 percent of nursing home staff nationwide received the required COVID-19 vaccine doses, and an estimated 56 percent of staff nationwide received a booster dose1
- An insurance profile of rural America: chartbook : key facts about insurance coverage and healthcare access in rural America1
- An introduction to managed care in CHIP1
- Annual status report information and other submissions for postmarketing requirements and commitments: using forms FDA 3988 and FDA 3989 : guidance for industry1
- Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report1
- Antimicrobial susceptibility test (AST) system devices: updating breakpoints in device labeling : guidance for industry and Food and Drug Administration staff1
- Antiviral drugs: Economic incentives and strategies for pandemic preparedness : report to congressional committees1
- Application of human factors engineering principles for combination products: questions and answers : guidance for industry and FDA staff1
- Are older workers good for business?1
- Assessing the credibility of computational modeling and simulation in medical device submissions: guidance for industry and Food and Drug Administration staff1
- Becoming less usual: understanding the decline in the number of people with a usual source of care1
- Behavioral health diagnoses and treatment services for children and youth involved with the child welfare system1
- Belimumab and voclosporin for lupus nephritis: effectiveness and value : final report1
- Bempedoic acid and inclisiran for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD: Effectiveness and value : final report1
- Benefit-risk assessment for new drug and biological products: guidance for industry1
- Breakthrough Devices Program: guidance for industry and Food and Drug Administration staff1
- Building a safe workplace and community1